Dissecting the mode of action of various HIV-inhibitor classes in a stable cellular system

被引:31
作者
Klimkait, T [1 ]
Stauffer, F [1 ]
Lupo, E [1 ]
Sonderegger-Rubli, C [1 ]
机构
[1] Novartis Pharma Inc, Basel, Switzerland
关键词
D O I
10.1007/s007050050447
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We describe a stable and sensitive HN evaluation system, which discriminates HIV-specific membrane fusion and early transcription events and is suitable for high-throughput inhibitor screening. A human lymphocytic line, constitutively producing infectious HIV-1, serves as Env-positive donor. A second indicator cell line carries a silent HIV-1 LTR lacZ reporter plasmid. A bicellular cocultivation setup allows titration and standardization of "fusion-induced gene stimulation (FIGS)" events. With few manipulations aspects of fusion and/or LTR induction can be distinguished and simultaneously assayed. Anti-Env-VS antibodies prevent fusion and subsequent lacZ induction, and a Tat-specific inhibitor blocks only lacZ induction in a dose dependent manner without affecting membrane fusion. The LTR reporter is readily activated by Tat from HIV-1, HIV-2, or SIV and it responds to exogenous Tat protein. The reporter system is sensitive enough to detect single infection events on pre-seeded layers of indicator cells, which renders it potentially useful for direct virus quantification in patients' material. Moreover, our system allows to control and normalize DNA transfection efficiencies of HIV-derived plasmids. This aspect is particularly valuable for studies of RT- and protease-inhibitors and resistances, where p24 or supernatant reverse transcriptase, otherwise standard virus readouts, can be directly affected by inhibitors or mutations.
引用
收藏
页码:2109 / 2131
页数:23
相关论文
共 41 条
[1]  
ADACHI A, 1986, J VIROL, V59, P1157
[2]   HIV-1 INDICATOR CELL-LINES [J].
AKRIGG, A ;
WILKINSON, GWG ;
ANGLISS, S ;
GREENAWAY, PJ .
AIDS, 1991, 5 (02) :153-158
[3]   CGP-53437, AN ORALLY BIOAVAILABLE INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE WITH POTENT ANTIVIRAL ACTIVITY [J].
ALTERI, E ;
BOLD, G ;
COZENS, R ;
FAESSLER, A ;
KLIMKAIT, T ;
LANG, M ;
LAZDINS, J ;
PONCIONI, B ;
ROESEL, JL ;
SCHNEIDER, P ;
WALKER, M ;
WOODSCOOK, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (10) :2087-2092
[4]   EFFICIENT TRANSACTIVATION BY THE HIV-2 TAT PROTEIN REQUIRES A DUPLICATED TAR RNA STRUCTURE [J].
BERKHOUT, B ;
GATIGNOL, A ;
SILVER, J ;
JEANG, KT .
NUCLEIC ACIDS RESEARCH, 1990, 18 (07) :1839-1846
[5]   SEQUENCE REQUIREMENTS FOR ACTIVATION OF THE HIV-1 LTR BY HUMAN CYTOMEGALOVIRUS [J].
BIEGALKE, BJ ;
GEBALLE, AP .
VIROLOGY, 1991, 183 (01) :381-385
[6]   HYGROMYCIN-B PHOSPHOTRANSFERASE AS A SELECTABLE MARKER FOR DNA TRANSFER EXPERIMENTS WITH HIGHER EUKARYOTIC CELLS [J].
BLOCHLINGER, K ;
DIGGELMANN, H .
MOLECULAR AND CELLULAR BIOLOGY, 1984, 4 (12) :2929-2931
[7]   A BETA-GALACTOSIDASE HYBRID PROTEIN TARGETED TO NUCLEI AS A MARKER FOR DEVELOPMENTAL STUDIES [J].
BONNEROT, C ;
ROCANCOURT, D ;
BRIAND, P ;
GRIMBER, G ;
NICOLAS, JF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (19) :6795-6799
[8]   ONCOGENE ACTIVATION OF HIV-LTR-DRIVEN EXPRESSION VIA THE NF-KAPPA-B BINDING-SITES [J].
BRUDER, JT ;
HEIDECKER, G ;
TAN, TH ;
WESKE, JC ;
DERSE, D ;
RAPP, UR .
NUCLEIC ACIDS RESEARCH, 1993, 21 (22) :5229-5234
[9]   ARGININE-MEDIATED RNA RECOGNITION - THE ARGININE FORK [J].
CALNAN, BJ ;
TIDOR, B ;
BIANCALANA, S ;
HUDSON, D ;
FRANKEL, AD .
SCIENCE, 1991, 252 (5009) :1167-1171
[10]   DEVELOPMENT OF A SENSITIVE QUANTITATIVE FOCAL ASSAY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTIVITY [J].
CHESEBRO, B ;
WEHRLY, K .
JOURNAL OF VIROLOGY, 1988, 62 (10) :3779-3788